Legendary breast cancer researcher Carol Fabian reflects on the progress of research and ...
Robin Love's participation in a clinical trial at The University of Kansas Cancer Center 18 years ago led to significant advancements in breast cancer treatment. Dr. Carol Fabian highlights the progress in understanding breast cancer as multiple diseases, with 70-80% responding well to treatment. Love's HER2-positive breast cancer, once aggressive, is now survivable, inspiring her son to become a doctor. Fabian emphasizes the importance of clinical trials and precision medicine in improving survivorship and early detection.
Reference News
Robin Love's participation in a clinical trial at The University of Kansas Cancer Center 18 years ago led to significant advancements in breast cancer treatment. Dr. Carol Fabian highlights the progress in understanding breast cancer as multiple diseases, with 70-80% responding well to treatment. Love's HER2-positive breast cancer, once aggressive, is now survivable, inspiring her son to become a doctor. Fabian emphasizes the importance of clinical trials and precision medicine in improving survivorship and early detection.